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Abstract. Recently a framework was presented to assess whether pediatric covariate models for
clearance can be extrapolated between drugs sharing elimination pathways, based on extraction ratio,
protein binding, and other drug properties. Here we evaluate when a pediatric covariate function for
midazolam clearance can be used to scale clearance of other CYP3A substrates. A population PK
model including a covariate function for clearance was developed for midazolam in children aged 1–
17 years. Commonly used CYP3A substrates were selected and using the framework, it was assessed
whether the midazolam covariate function accurately scales their clearance. For eight substrates,
reported pediatric clearance values were compared numerically and graphically with clearance values
scaled using the midazolam covariate function. For sildenaﬁl, clearance values obtained with
populationPKmodeling basedonpediatric concentration-timedatawere comparedwith those scaled
with themidazolam covariate function. According to the framework, a midazolam covariate function
will lead to systemically accurate clearance scaling (absolute prediction error (PE)< 30%) forCYP3A
substrates binding to albumin with an extraction ratio between 0.35 and 0.65 when binding < 10% in
adults, between 0.05 and 0.55 when binding > 90%, and with an extraction ratio ranging between
these values when binding between 10 and 90%. Scaled clearance values for eight commonly used
CYP3A substrates were reasonably accurate (PE< 50%). Scaling of sildenaﬁl clearance was accurate
(PE < 30%). We deﬁned for which CYP3A substrates a pediatric covariate function for midazolam
clearance can accurately scale plasma clearance in children. This scaling approach may be useful for
CYP3A substrates with scarce or no available pediatric PK information.
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INTRODUCTION
To deﬁne the optimal ﬁrst-in-child dose during drug
development and to develop pediatric dose recommenda-
tions for clinical practice, accurate scaling of the plasma
clearance of drugs is essential (1–3). This is of particular
relevance as performing dedicated pharmacokinetic (PK)
studies for all drugs in all pediatric (sub)populations may
not be feasible because it would take too many resources.
Moreover, this may not even be necessary when other
methods are available and could therefore even be
considered unethical. One proposed approach shares PK
information of drugs eliminated by the same pathway by
extrapolating covariate relationships for clearance between
drugs (4). This has already been successfully applied for
scaling pediatric clearance for drugs glucuronidated by
UGT2B7 enzymes and also for drugs eliminated by
glomerular ﬁltration (4–6).
Within this context, recently, a framework was pre-
sented by Calvier et al. for hepatically metabolized drugs
identifying the conditions for which between-drug extrapo-
lation is systematically accurate (7). This framework takes
into account changes in physiological parameters with age,
including changes in (hepatic) blood ﬂow, plasma protein
concentrations, hematocrit, liver size, the amount of micro-
somal protein per gram of liver, and the ontogeny of
isoenzyme expression (the microsomal intrinsic clearance)
(7). One of the key ﬁndings of this framework was that the
accuracy of this scaling method depends on the fraction
metabolized by the isoenzyme pathway for which plasma
clearance is scaled, on the hepatic extraction ratio of both the
probe drug and the evaluated drugs in adults, on the type of
binding plasma protein, and on the unbound drug fraction
(fu) in adults (7).
As many drugs are eliminated by the cytochrome P450
(CYP) 3A enzyme family (8,9), a pediatric covariate function
for CYP3A-mediated clearance may aid in scaling clearance
of CYP3A substrates. Midazolam is an established probe
drug for CYP3A-mediated clearance (10,11), mainly metab-
olized by CYP3A4, and to a lesser extent by CYP3A5 (12),
and has an intermediate extraction ratio (13). Our aim is to
evaluate when a pediatric covariate function for midazolam
clearance can be used to scale clearance of other CYP3A
substrates in children, taking into account the recent insights
of the developed framework (7).
METHODS
Overall Approach
A population PK model for midazolam in children was
developed based on concentration-time data, to establish a
pediatric covariate function for midazolam clearance. Next, we
selected a range of drugs that are CYP3A substrates that are
commonly prescribed in children, covering compounds prescribed
for varying indications in different therapeutic areas, with oral or
intravenous administration, and with different drug properties, i.e.,
alprazolam (14), atorvastatin (15), cisapride (16), domperidone
(17), quinidine (18), sildenaﬁl (19), simvastatin (20), solifenacin
(21), sufentanil (22), sirolimus (23), tacrolimus (24), tamsulosin
(25), and vincristine (26). Based on the drug properties of these
CYP3A substrates, we used the framework of Calvier et al. (7) to
deﬁne which age the covariate function for midazolam can be used
for accurate scaling of pediatric clearance of the CYP3A substrates
from adult clearance values. For eight of the selected CYP3A
substrates, pediatric and adult clearance values were available in
literature, allowing for the assessment of the accuracy of the scaling
function by comparing pediatric clearance values that were scaled
from adult clearance values using the covariate function for
midazolam to the published literature clearance values in children.
Furthermore, for sildenaﬁl, concentration-time data were available
from 156 children (27). Using these data, we developed two
pediatric population PK models for sildenaﬁl; one using the
pediatric covariate function of midazolam clearance directly and
one inwhich the covariate relationship for clearancewas optimized
using a data-driven analysis, after which, the performance of both
models, as well as the estimated and scaled clearance values, was
compared.
Midazolam Population PK Model
Midazolam PK data were available from 31 patients (15
male, 16 female) from the Children’s Hospital of Philadel-
phia, PA (Table I), with a median age of 8 years of age (range
1–17 years) and a median body weight of 30.2 kg (range 9.5–
83.2 kg) (28). Before participation, signed informed consent,
by the subject’s parents or guardian, and assent were
obtained. Children undergoing surgery were included if they met
the criteria I or II of the American Society of Anesthesiologist’s
(ASA) classiﬁcation.Amedian dose of 12.5mg (range 3–15mg) of
midazolam was administered as oral suspension (5 mg/mL, Roche
Table I. Study and Patient Characteristics of the Midazolam and Sildenaﬁl PK Studies
Midazolam Sildenaﬁl
Indication Pre-operatively Pulmonary arterial hypertension
Number of patients 31 156
Number of samples 327 591
Samples/patient* 10 (8–11) 4 (1–4)
Age (years)* 8 (1–17) 10 (1–17)
Body weight (kg)* 30.2 (9.5–83.2) 28.0 (8.2–106.0)
Male/female, n (%) 15/16 (48/52%) 57/99 (37/63%)
Dose (mg)* 12.5 (3–15) 20 (10–80)
*median (range)
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Laboratories) to the patients pre-operatively. Blood was densely
sampled for midazolam plasma concentrations around 0.25, 0.5, 1,
1.5, 2, 3, 4, 6, 8, 10, and 22h after dose administration,with amedian
of 10 samples per patient (range 8–11). Blood was centrifuged and
plasma samples stored at <− 20 °C, until midazolam plasma
concentrations were determined using LC/MS (28).
ApopulationPKmodelwasdevelopedusingnon-linearmixed
effects modeling (NONMEM version 7.3, ICON, Globomax LLC,
Ellicott, MD, USA; Perl-speaks-NONMEM (PsN) version 4.2.0,
Uppsala, Sweden; and Pirana 2.9.0, Pirana Software & Consulting
BV, Denekamp, the Netherlands) based on ﬁrst-order conditional
estimation with interaction. R (version 3.3.1) and RStudio (version
0.98.1078)wereusedfordatavisualization.Severalstructuralmodels
were considered, including 1-, 2-, and 3-compartmentalmodels, and
evaluated based on criteria for model stability, goodness-of-ﬁt, and
parameter precision, and on comparisons of the objective function
values (OFV, − 2 × log-likelihood), using a signiﬁcance level of
p< 0.05. The absorption rate could not be estimated and was
thereforeﬁxedat3.5h−1(29),whichresultsina tmaxaround0.5hpost-
dose, which is in agreementwith known values.
Interindividual variability in the estimated parameters
for clearance and central volume of distribution was included
in the model by the following equation:
Pi ¼ θTV  eηi ð1Þ
in which Pi is the individual parameter estimate for
individual i, θTV is the typical value of the parameter in the
studied population, and ηi is a random variable for the ith
individual from a normal distribution with a mean of zero and
variance of ω2, assuming a log-normal distribution for the
parameter value in the population.
To describe residual unexplained variability, a proportional
error model, an additive error model, and a combination of the
proportional and additive error were considered. The jth observed
concentration of the ith individual (Yij) was modeled according to
Yij ¼ Cpred;ij  1þ ε1ij
 þ ε2ij ð2Þ
where Cpred,ij is the jth predicted midazolam concentration of
the ith individual, and εij is a random variable from a normal
distribution with a mean of zero and variance of σ2, with ε1
the proportional error and ε2 the additive error.
A systematic covariate analysis was performed for the
estimated model parameters in which age, body weight, and
sex were tested for statistical signiﬁcance. For sex, the typical
value (θTV) for girls was estimated relative to the value for
boys. The remaining continuous covariates body weight and
age were tested using a power (Eq. 3) function:
Pi ¼ θTV  COViCOVmed
 θCOV
 eηi ð3Þ
where Pi is the individual parameter estimate for individual i
with a covariate value of COVi, θTV is the parameter value for
a typical individual with a median covariate value (COVmed),
θCOV is the estimated exponent, and ηi is a random variable
as described above (Eq. 1). For the forward inclusion of a
covariate, a drop in OFV by at least 6.64 points (p < 0.01) was
considered statistically signiﬁcant, while for the backward
deletion a more stringent p value (p < 0.005, ΔOFV > 7.88)
was used. In addition, the interindividual variability in the PK
parameter or the residual variability should decrease for a
covariate to be retained in the model.
To evaluate whether the model described the observed
concentrations well, goodness-of-ﬁt plots were assessed.
These diagnostic plots include observed versus population-
and individual-predicted concentrations and conditional
weighted residuals (CWRES) versus population-predicted
concentrations and versus time. To evaluate model stability
and parameter precision, a bootstrap analysis (n = 250) was
performed. Finally, a normalized prediction distribution error
(NPDE) analysis was performed using the NPDE package in
R (30), with n = 1000 simulations to evaluate whether the
model can accurately predict the concentration and capture
the observed variability.
Between-Drug Extrapolation Potential of Midazolam
Clearance to Other CYP3A Substrates
The previously published framework on between-drug
extrapolation of covariate functions (7) was used to assess,
based on the drug properties of CYP3A substrates, whether
between-drug extrapolation of the covariate relationship for
midazolam would lead to accurate scaling of the pediatric
clearance of the selected CYP3A substrates. For this, the
relevant drug properties, i.e., the extraction ratio, the plasma
protein to which the drug is binding, and the fu for midazolam
and the selected drugs were obtained from literature. In this
analysis, the selected drugs were assumed to exclusively bind
to either human serum albumin (HSA) or α1-acid glycopro-
tein (AAG), while midazolam was assumed to bind to either
HSA (for comparison with HSA-binding drugs) or to AAG
(for comparison with AAG-binding drugs).
Using the extraction ratio and the fu of the selected
CYP3A substrates that were considered within the results
from the framework (7), it was assessed to what age clearance
scaling with the covariate function of midazolam would
certainly be accurate for the selected drugs. Drugs were
selected of which it has been reported that CYP3A is the
“major” pathway for elimination, and we assumed CYP3A
metabolism to be responsible for ≥ 75% of the total
metabolism for both midazolam and all selected substrates.
Based on the extraction ratio and fu from midazolam, we also
derived general criteria for systematically accurate clearance
scaling for CYP3A substrates using the covariate function for
midazolam clearance according to the framework.
Comparison of Scaled Versus Reported Pediatric Clearance
Values
For the selected CYP3A substrates for which both pediatric
and adult clearance values were reported in literature, we applied
the pediatric covariate function for midazolam clearance to the
reported adult clearance values to scale for pediatric clearance
values. For this we assumed that typical adults have a body weight
of 70 kg. We graphically compared the scaled typical clearance
values with the reported pediatric clearance values. Moreover, we
calculated the prediction error (PE) for three typical subjects (an
infant of 10 kg, a child of 20 kg, and an adolescent of 50 kg) based
on literature values for pediatric clearance using Eq. 4:




with CLscaled the scaled clearance value and CLref the reported
pediatric clearance. An absolute PE of < 30% was considered
accurate, an absolute PE of 30–50% reasonably accurate, and an
absolute PE of ≥ 50% inaccurate.
Sildenafil Population PK Models
Sildenaﬁl PK data from a previously published study (27)
were made available by Pﬁzer Inc. In this study, sildenaﬁl PK data
were collected from 156 (57 male, 99 female) patients in a
randomized, double-blind, placebo-controlled, dose ranging, par-
allel group study of oral sildenaﬁl for the treatment of childrenwith
pulmonary arterial hypertension (27,31). Subjects included children
ranging in age from 1 to 17 years (median 10 years), with a median
body weight of 28.0 kg (range 8.2–106 kg) (Table I). A median of
four samples per patient (range 1–4) was available, with a total of
591 measurements available for analysis. Samples were taken at
steady-state at trough and around three, six, and eight hours post-
dose. Patients were randomly assigned to a low-, medium-, or high-
dose group (n= 39, n= 48, and n= 69, respectively), and the
dosages were weight-stratiﬁed, with a medium dose of 10, 20, and
40 mg and a high dose of 20, 40, and 80 mg for patients of 8–20 kg,
20–45 kg or > 45 kg, respectively. The low dose was 10 mg for all
patients > 20 kg, and patients with a body weight ≤ 20 kg received
either amediumor high dose, as no drug effect was expectedwith a
lower dose than 10 mg (27,31). In the population PK analysis, the
samples without recorded sampling times were excluded.
Based on these data, a “reference model” was developed in
the same manner as described for midazolam. The absorption
rate constant could not be estimated and was therefore ﬁxed at
1 h−1, leading to a maximum concentration around two hours
post-dose, which was before the ﬁrst sample was taken.
The extrapolation potential of the covariate function for
midazolam clearance was evaluated in a second population PK
model referred to as the “extrapolation model.” This model was
kept the same as the referencemodel, except the clearancewas not
estimated, but scaled from an apparent CL/F value of 100 L/h for
adults, which was derived from reported systemic clearance and
oral bioavailability values of 41 L/h and 0.41 L/h, respectively (32),
using the covariate function for midazolam clearance.We assumed
the same bioavailability in adults and pediatric patients.
The reference and extrapolation models were evaluated
in the same manner as the midazolam PK model (see under
“Midazolam Population PK Model”).
Sildenaﬁl clearance values from the sildenaﬁl the “refer-
ence model” (CLref) and the sildenaﬁl “extrapolation model”
(CLscaled) were compared graphically. For a numerical
comparison of both sildenaﬁl models, typical clearance values
for three typical subjects (an infant of 10 kg, a child of 20 kg,
and an adolescent of 50 kg) were calculated, and a PE for
clearance was calculated using Eq. 4.
RESULTS
Midazolam Population PK Model
For midazolam, a two-compartmental model with body
weight, included in an exponential covariate relationship on
clearance, volumes of distribution, and intercompartmental
clearance, best described the data (Table II, ﬁg. S2, S3). As
midazolam was administered orally, apparent parameters for
clearance and volume of distribution were obtained. For a typical
individual of 30.2 kg, apparent clearance was 102.6 L/h, and the
exponent, in the exponential equation relating body weight and
clearance, was found to be 0.874 (Table II). As a result, this
pediatric covariate function was used to scale CYP3A-mediated
clearance in the between-drug extrapolation:
CLpediatric ¼ CLadult  WT70
 0:874
ð5Þ
Between-Drug Extrapolation Potential of Midazolam
Clearance to Other CYP3A Substrates
The obtained drug properties of midazolam and the selected
CYP3A substrates required for between-drug extrapolation of
clearance are listed in Table SI (33–54). Figure S1 shows down to
Table II. Model Parameter Estimates for the Midazolam PK Model and the Bootstrap Results Based on n = 250 Resampling
Parameter Model estimate (RSE) Bootstrap median (90 CI)
Midazolam clearance†
CLi =CL30.2 kg × (WTi/30.2)
k1
(CL/F)30.2 kg (L/h) 102.6 (9%) 101.4 (89.1–118.2)
k1 0.874 (13%) 0.901 (0.698–1.11)
Volume of distribution†
Vc,i =Vc,30.2 kg × (WTi/30.2)
k2
(Vc/F)30.2 kg (L) 156 (25%) 141 (76.5–210)
k2 1.88 (17%) 2.15 (1.43–3.30)
Peripheral volume†
Vp,i =Vp,30.2 kg × (WTi/30.2)
k3
(Vp/F)30.2 kg (L) 255 (14%) 252 (197–338)
k3 0.91 (23%) 0.88 (0.60–1.21)
Intercompartmental clearance†
Qi =Q30.2 kg × (WTi/30.2)
k4
(Q/F)30.2 kg (L/h) 121.8 (21%) 115.6 (73.7–163)
k4 0.75 ﬁx 0.75 ﬁx
Absorption rate constant ka (h
−1) 3.5 ﬁx 3.5 ﬁx
IIV clearance ω2 CL/F 0.158 (41%) 0.145 (0.063–0.259)
IIV volume of distribution ω2 Vc/F 1.19 (27%) 1.06 (0.64–1.71)
Proportional error σ2 0.283 (13%) 0.272 (0.222–0.346)
RSE is the relative standard error, and 90 CI is the 90% conﬁdence interval representing the 5th and 95th percentiles. Interindividual and
residual variability values are shown as variance estimates
† Parameters are apparent parameters, as only oral data was included
   81 Page 4 of 11 The AAPS Journal          (2019) 21:81 
what age the clearance of the selected substrates can at least be
extrapolated fromadult valueswith the covariate relationships for
midazolam clearance, based on the differences in extraction ratio
and fu according to the framework that was previously reported
(7). Based on this information, Fig. 1 was derived showing when
scaling of pediatric clearance of a CYP3A substrate will be
accurate depending on its extraction ratio and fu values in adults.
This ﬁgure shows that this method will accurately scale pediatric
clearance values down to neonates of 1 day of age for alprazolam,
atorvastatin, quinidine, sildenaﬁl, solifenacin, sufentanil, and
tacrolimus, while for the other drugs clearance will be at least
accurately scaled down to infants of 1 month (sirolimus) and
6 months of age (cisapride, domperidone, and vincristine).
Tamsulosin clearance scaling will be accurate down to at least
2 years of age, while for simvastatin accurate scaling down to
5 years of age may not even be possible (Fig. 1).
From Fig. 1 it can also be derived that a pediatric
covariate function for midazolam can be used to scale
CYP3A-mediated clearance across all ages including neo-
nates (i.e., green bars) of HSA-bound substrates which are
highly protein bound (> 90%, fu≤ 0.1), provided the extrac-
tion ratio in adults ranges between 0.05 and 0.55. Similarly,
for HSA-bound substrates with low protein binding (< 10%,
fu≥ 0.9), the drug to which the covariate function can be
extrapolated should have an extraction ratio between 0.35
and 0.65. In between these extreme percentages of binding to
HSA, the required extraction ratio gradually changes be-
tween these values (green bars, Fig. 1). For AAG-bound
drugs, fewer combinations of drug properties lead to accurate
scaling based on a midazolam pediatric covariate function,
with no scenarios for drugs with low or intermediate protein
binding (< 60%, fu≥ 0.4), while an extraction ratio of 0.4–0.6
or 0.1–0.5 in adults leads to accurate scaling for drugs that are
around 90% or ≥ 97.5% bound, respectively (Fig. 1).
Comparison of Scaled Versus Reported Pediatric Clearance
Values
Obtained pediatric and adult clearance values of CYP3A
substrates are summarized in Table SI (32,35,55–65). In
Fig. 2, the scaled clearance values are shown together with
the reported pediatric clearance values for the various
substrates versus body weight. Table IV lists the calculated
prediction errors for the three typical pediatric individuals.
For most drugs, the scaled covariate relationships fall within
the range of observed values, except for vincristine and
sirolimus. The calculated PE values also show that scaled
vincristine and sirolimus clearance values are inaccurate;
although with a PE value of 64.3% and 58.3%, respectively,
this inaccuracy is not extreme. The PE values for all other
drugs are < 50%, indicating accurate or reasonably accurate
scaling of clearance in infants, children, and adolescents.
Sildenafil Population PK Models
The reference model and extrapolation model for
sildenaﬁl described the sildenaﬁl concentrations with a one-
compartmental model. Table III presents model parameters
and bootstrap values for both models and the goodness-of-ﬁt
plots and results from the NPDE analyses are presented in
ﬁg. S4 and ﬁg. S5, respectively. These results show that
descriptive and predictive properties of both models are
similar.
In the reference model, apparent sildenaﬁl clearance for a
typical individual of 28 kg was found to be 41.9 L/h, and clearance
increased exponentially with increasing body weight (exponent of
1.08 [RSE 11%]), leading to an apparent clearance of 113 L/h for a
70-kg individual. In the extrapolation model, apparent clearance
was scaled using Eq. 5, with a CLadult of 100 L/h for a 70-kg
Drugs binding to HSA Drugs binding to AAGa b
Fig. 1. Prediction of the age down towhich the pediatric covariate function forCYP3A-mediatedmidazolam clearance can be used to accurately scale
clearance of CYP3A substrates with speciﬁc drug properties. Extraction ratio values of the tested CYP3A substrates are plotted versus the fraction
unbound (fu) of the test drugs in adults. The color schemewas obtained from the published framework (7) and represents hypotheticalmodel-test drug
combinations that lead to systematically accurate scaling of clearance in children down to 1 day (green), 1 month (purple), 6 months (orange), 1 year
(blue), 2 years (pink), and 5 years of age (yellow). Red indicates that scaling is not systematically accurate in children of 5 years and younger. The black
data points represent the included test drugs and their extraction ratio and fu values. Panel a shows drugs binding to albumin (HSA), while panel b
shows drugs binding to α1-acid glycoprotein (AAG). Modiﬁed from Calvier et al. (7) (with permission)
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individual, leading to a scaled apparent clearance of 44.9 L/h for a
28-kg individual. As shown in a graphical comparison in Fig. 3a,
both covariate relationships are very similar, with only a small
difference in clearance values between the twomodels for children
with the lowest body weight. Figure 3 b shows that when individual
clearance predictions by both models are plotted versus age, the
loess function for these relationships is also similar with the small
difference in the youngest age range. These small discrepancies
may be due to the small number of individuals in the youngest age
group (1–2 years of age) in the population receiving midazolam
used for establishing the pediatric covariate function.
The PE for clearance increases with a decreasing age, with a
PE of − 5.2%, 14.6%, and 32.1%, in an adolescent, child, and
infant, respectively, indicating that with a decreasing age and body
weight, the extrapolation model yields a larger overprediction of
clearance. However, the scaled clearance values are within the
range of observed clearance values, which show a high variability
throughout the pediatric age range (Fig. 3b).
DISCUSSION
Accurate scaling of plasma clearance is essential to establish
optimal ﬁrst-in-child doses during drug development and for the
development of pediatric dose recommendations. As many drugs
are metabolized by CYP3A enzymes and midazolam is a
commonly accepted probe drug for CYP3A, we aimed to evaluate
Fig. 2. Scaled and reported clearance values versus body weight for various CYP3A substrates. Clearance (or apparent clearance) values are
based on the between-drug extrapolation of the pediatric covariate function for CYP3A-mediated midazolam clearance and reported adult
clearance values (black) and based on reported pediatric clearance values in literature (gray), for sildenaﬁl (a), atorvastatin (b), quinidine (c),
sirolimus (d), sufentanil (e), tacrolimus (f), tamsulosin (g), and vincristine (h). The vertical dotted line (gray) indicates the body weight down to
which systemically accurate clearance scaling is predicted to be possible according to the framework (7). For the reported clearance values the
following is depicted: aMean sildenaﬁl clearance (line) with minimal and maximal reported values (gray area). b Typical atorvastatin clearance
(line) ± 46.3% (%CV, gray area). c Mean quinidine clearance (line) ± 2 SD (gray area) and individual-reported clearances (closed circles). d
Individual-reported sirolimus clearances (closed circles). e Mean sufentanil clearance (line) ± 2 SD (gray area). f Typical tacrolimus clearance




, and σ2 = 0.16, gray area). g Typical tamsulosin clearance (line) ± 54.4% (%CV, gray area). h
Individual-reported vincristine clearances, corrected for body surface area (closed circles)
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when a pediatric covariate function for CYP3A-mediated midazo-
lam clearance can be used to scale pediatric clearance of CYP3A
substrates given the recently reported guidance on between-drug
extrapolation of covariate models.
Whether in this case, scaling of pediatric clearance of CYP3A
substrates based on a covariate function from a pediatric
population PK model for midazolam is accurate may depend on
the drug properties as was reported by Calvier et al. before (7). We
used this previously developed framework (7) to assess forwhich of
the selected CYP3A substrates scaling with the pediatric covariate
function from midazolam will lead to accurate clearance values
(Fig. 1). The color code in Fig. 1 indicates down towhich age scaling
of clearance is expected to be systemically accurate based on the
extraction ratio and fu in adults. Each colored dot in this graph
represents multiple drugs with differences in the remaining drug
properties (i.e., blood-to-plasma partitioning and afﬁnity to isoen-
zymes) and it should be noted that when the framework predicts
that scaling of clearance is not systemically accurate for all drugs
with the indicated combination of drug properties, there may still
be drugs within the set of drugs represented by a data point for
which this scaling is accurate. In those cases, it can however not be
predicted a priori whether this will be the case for each of the
individual drugs (7).
For the selected CYP3A substrates alprazolam, atorva-
statin, cisapride, domperidone, quinidine, sildenaﬁl,
solifenacin, sufentanil, sirolimus, tacrolimus, and vincristine,
based on differences in fu and extraction ratio in comparison
with midazolam, scaling of clearance with the covariate
function of midazolam is expected to be accurate down to
children of at least 1 year of age and for some drugs even to
neonates and infants (Fig. 1).
Several approaches and methods for scaling of clearance
in children have been described in literature, including scaling
of clearance using a body weight–based exponential function
with exponents of, e.g., 0.67, 0.75, or 1. While some studies
showed that allometric scaling may be a reasonable approach
(66,67) and other studies disagreed (68,69), in a systematic
assessment of the applicability of body weight–based scaling
with a ﬁxed exponent of 0.75, it was found that this approach
leads to increasingly inaccurate scaled values with decreasing
age, reaching prediction errors of up to 278% in neonates
(70). Also, other phenotyping studies have used probe drugs
Table III. Model Parameter Estimates for the Sildenaﬁl “Reference Model” Versus the Sildenaﬁl “Extrapolation Model” and the Bootstrap
Results for both Models Based on n = 250 Resampling
Parameter Reference model Extrapolation model
Model estimate (RSE) Bootstrap (90 CI) Model estimate (RSE) Bootstrap (90 CI)
Sildenaﬁl clearance†
CLi =CL70 kg × (WTi/70)
k1
(CL/F)70 kg (L/h) 113 (13%) 112 (84.6–149) 100 ﬁx 100 ﬁx
k1 1.08 (11%) 1.05 (0.82–1.30) 0.874 ﬁx 0.874 ﬁx
Volume of distribution†
Vi =V28 kg × (WTi/28)
k2
(V/F)28 kg (L) 540 (33%) 561 (311–1424) 590 (29%) 574 (389–1134)
k2 3.18 (10%) 3.17 (2.41–4.27) 3.18 (10%) 3.16 (2.49–4.01)
Absorption rate constant ka (h
−1) 1 ﬁx 1 ﬁx 1 ﬁx 1 ﬁx
IIV clearance ω2 CL/F 0.493 (14%) 0.487 (0.363–0.631) 0.510 (13%) 0.512 (0.397–0.650)
Proportional error σ2 0.627 (7%) 0.616 (0.538–0.703) 0.651 (8%) 0.646 (0.564–0.738)
RSE is the relative standard error, and 90 CI is the 90% conﬁdence interval representing the 5th and 95th percentiles. Interindividual and
residual variability values are shown as variance estimates
† Parameters are apparent parameters, as only oral data was included
Fig. 3. Sildenaﬁl apparent clearance versus body weight (a) and versus age (b) for the sildenaﬁl reference model (gray) and based on between-
drug extrapolation of clearance (black) with points representing the individual-predicted clearance by the reference model. In panel a, the lines
represent population-predicted clearance values directly derived from the body weight–based covariate relationship, while in panel b, the lines
represent the loess function summarizing the population-predicted clearance values with a 95% conﬁdence interval (shaded area)
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to predict clearance of a drug sharing its elimination pathway
(71–74). These phenotyping studies include studies applying
the “cocktail” approach with ﬁve drugs reﬂecting clearance
by ﬁve CYP enzymes including CYP3A, which has been
considered to be predictive of drug-drug interactions with
regard to these enzymes (75), but there is no data on how this
approach may predict pediatric clearance. The concept of
using probe drugs for drug clearance in the pediatric
population by extrapolating pediatric covariate functions for
clearance for drugs sharing elimination pathways was there-
fore developed, and this method had already been successful
in scaling pediatric clearance for UGT2B7 substrates and for
drugs eliminated through glomerular ﬁltration (4–6). Later, a
systematic assessment of this method deﬁned the prerequi-
sites for systematically accurate scaling with this technique
(7). In the current work, we illustrate how the knowledge
obtained in that analysis can be applied. Moreover, we add
CYP3A metabolism to the list of elimination pathways for
which between-drug extrapolation of pediatric covariate
relationships for clearance has been successfully applied.
Between-drug extrapolation of clearance on the basis of a
pediatric covariate function for CYP3A-mediated midazolam
clearance, indeed, led to accurate or reasonably accurate scaling
of pediatric clearance of most of the selected CYP3A substrates in
children (Table IV, Fig. 2). The pediatric covariate function for
midazolam clearance can accurately scale pediatric clearance of
CYP3A substrates down to at least 1 year of age for a large number
of relevant substrates including sildenaﬁl, atorvastatin, quinidine,
sufentanil, tacrolimus, and tamsulosin. This indicates accurate
predictions for 75% (6 out of 8) of the evaluated compounds. In
addition to reported clearance values, for sildenaﬁl, concentration-
time data were available as well. With these data, it was further
conﬁrmed that the between-drug extrapolation of the covariate
relationship of midazolam clearance yields accurate clearance
predictions.
Contrary to what was expected based on the theoretical
framework, scaled clearance values of sirolimus and vincristine (2
out of 8 evaluated compounds) were inaccurate compared with
reported literature values (PE> 50%,Table IV). For sirolimus, this
may be due to the known induction of hepatic CYP3A activity and
possibly altered hepatic P-glycoprotein expression (76). The impact
of hepatic transporters was not taken into consideration in the
frameworkbyCalvieret al., because the impactof these transporters
on clearance and their maturation patterns in children remains
largely unknown. The scaling of vincristine may be inaccurate,
because it is predominantly metabolized by CYP3A5 (77), with a
relative smaller contribution of CYP3A4-mediated metabolism
comparedwithmidazolam,whilemidazolam ismainlymetabolized
byCYP3A4(12).NopharmacogenomicsdataonCYP3Apolymor-
phisms were collected, which could have explained some of the
observed interindividual variability in clearance. Other factors that
may affect the accuracy of our pathway-speciﬁc scaling approach,
apart from the hepatic extraction ratio and fu in adults, include that
the fraction eliminated by a certain pathwaymay be different from
the≥ 75%assumedhere. Ithas for instancebeenshownthat theage
downtowhichclearancecanaccuratelybescaled increaseswhenthe
contribution of CYP3Ametabolism to the overall hepatic metabo-
lism is decreasing (7). Additionally, the contribution of minor
elimination pathways to overall drug clearance has been ignored in
the current analysis. Moreover, scenarios for the between-drug
extrapolationof pediatric covariate functions for clearanceofHSA-
bound drugs to AAG-bound drugs have not been investigated;
therefore,weassumedmidazolamtobeAAG-boundwhenusing its
covariate function to scale the clearance of AAG-bound CYP3A
substrates. The impact of this assumption would be largest in
neonates and in the youngest children < 1 year of age; as in these
age groups, the concentration of AAG is known to vary more with
age than the concentration of HSA, due to the fact that AAG
concentrations take longer time to mature and reach adult levels
(78). It shouldalsobe taken intoaccount that stress anddisease state
may impact protein binding and thereby alter the unbound fraction
within an individual over time (79,80). Lastly, as in the sildenaﬁl PK
study, not many samples were taken shortly after administration;




ﬁxing it at different values had no impact on the scaled clearance
values.
In this analysis, we only included midazolam PK data from
children > 1 year of age, and therefore, the pediatric covariate
function for midazolam clearance we developed in this analysis
cannot be used to scale clearance values of CYP3A substrates in
neonates and infants < 1 year of age. Extrapolation of the
covariate relationship to (preterm) neonates and infants is
anticipated to yield overprediction of clearance, as CYP3A-
mediated metabolism in this young age group is lower due to the
large impact of maturation in the ﬁrst weeks and months of life
(83). To be able to apply this covariate function to scale CYP3A-
mediated clearance in neonates and young infants up to 1 year of
age, the model should be extended with a covariate relationship
for clearance based on data from children < 1 year of age.
CONCLUSION
This analysis showed that a pediatric covariate relationship
describing how midazolam clearance changes throughout the
pediatric age range can be used to scale adult clearance values
for many other CYP3A substrates to pediatric clearance values.
Speciﬁcally, it was found that this approach is applicable to
Table IV. Prediction error (PE) of scaled clearance values using the
pediatric covariate function for CYP3A-mediated midazolam clear-
ance versus reported pediatric clearance values for three representa-
tive pediatric subjects of 10, 20, and 50 kg (Eq. 4), with negative and
positive values for under- and overpredicted clearance values,
respectively
Infant (10 kg) Child (20 kg) Adolescent (50 kg)
Atorvastatin − 26.7% − 20.1% − 10.5%
Quinidine − 33.5% − 39.0% − 12.8%
Sildenaﬁl 20.7% 10.6% − 1.4%
Sirolimus NA − 58.3% − 31.5%
Sufentanil − 10.3% − 12.0% 1.1%
Tacrolimus − 44.6% − 39.6% − 32.3%
Tamsulosin NA 8.1% 21.2%
Vincristine − 64.3% NA NA
NA denotes no pediatric or adult clearance values reported in
literature
Colors indicate an accurate prediction (absolute PE < 30%, bold), a
reasonably accurate prediction (absolute PE 30–50%, bold italics),
and an inaccurate prediction (absolute PE ≥ 50%, italics)
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accurately scale clearances of drugs that are mainly eliminated
by CYP3A-mediated metabolism with for example high protein
binding to HSA (> 90%) and a low to intermediate extraction
ratio of < 0.55 in adults. The possibility to scale clearance of
CYP3A substrates with the appropriate properties in children
from adult clearance using a pediatric covariate function for
CYP3A-mediated midazolam clearance may improve pediatric
dosing guidelines of CYP3A substrates for clinical practice and
may aid in determining the dose in ﬁrst-in-child studies involving
new CYP3A substrates depending on its drug properties. This
may be especially useful for CYP3A substrates in which scarce
or no pediatric PK information is available, for example for
alprazolam, domperidone, and solifenacin.
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